Modality
Radioligand
MOA
FcRni
Target
JAK2
Pathway
Lipid Met
Asthma
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
~Jul 2021
→ ~Oct 2022
Phase 2
Jan 2023
→ Aug 2029
Phase 2Current
NCT08355629
37 pts·Asthma
2023-01→2029-08·Active
37 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-08-243.4y awayPh3 Readout· Asthma
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2/3
Active
Catalysts
Ph3 Readout
2029-08-24 · 3.4y away
Asthma
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08355629 | Phase 2/3 | Asthma | Active | 37 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 | |
| IRO-8712 | Disc Medicine | Preclinical | JAK2 |